在PKS后,调整涉及两个P450细胞染色体的菌素
Hengyu Li1, Miao Sun1, Juan Zhao2
1School of Chemistry and Materials Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
Organic letters
|August 27, 2025
概括
研究人员阐明了Streptomyces platensis中的菌素路径,确定了新的衍生物和P450s PnT3和PnT7等关键酶. 这项工作为设计蛋白酸酶2A抑制剂提供了洞察力.
科学领域:
- 自然产品生物合成
- 酵素学
- 医学化学
背景情况:
- 菌素是一种具有潜在治疗用途的生物活性天然产品.
- 目前尚不完全了解菌素在PKS后的调整途径.
- 已知Streptomyces platensis是一种二次代谢产物.
研究的目的:
- 为了阐明Streptomyces platensis中色素后聚化酶 (PKS) 调整的完整途径.
- 识别和描述参与菌素修饰的酶.
- 确定作为蛋白质酸酶2A (PP2A) 抑制剂的菌素衍生物的结构活性关系 (SAR).
主要方法:
- 在体内基因失活研究 (pnT1-pnT7) 和体内生化测试的结合.
- 细胞P450酶的鉴定和功能特征.
- 对菌素衍生物的生物活性进行评估.
主要成果:
- 确定了七种菌素衍生物,其中包括四种新化合物.
- 鉴定了两个关键的P450酶:PnT3 (C-8/ C-25氧化) 和PnT7 (C-18化).
- 酸组对活性至关重要,而e-乳酸和C-3酸组则有害.
结论:
- 这项研究充分阐明了PKS后的菌素定制途径.
- 发现PnT3是一种多功能P450酶,可以调解复杂的氧化变化.
- 这些发现为设计新型PP2A抑制剂提供了结构-活性关系的基础.
相关概念视频
Drug Biotransformation: Overview
2.9K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.9K
Drug Metabolism: Phase II Reactions
4.1K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.1K
Allosteric Proteins-ATCase
5.9K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.9K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
79
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
79


